Z-Gly-Ala-Tyr-Bert (GALAT/DSAA)

Z-Gly-Ala-Tyr-Bert (CAS 1417334-25-8) is a specialized tripeptide building block employed in fragment condensation approaches to peptide synthesis. Z-Gly-Ala-Tyr-Bert features orthogonal protecting groups — the Z (benzyloxycarbonyl) group at the N‑terminus is cleaved by catalytic hydrogenation, while the tert‑butyl ester at the C‑terminus is removed under acidic conditions — allowing for selective deprotection strategies in complex synthetic routes. Additionally, Z-Gly-Ala-Tyr-Bert serves as a research tool for studying protease specificity, particularly for enzymes that recognize a Gly‑Ala‑Tyr motif. Moreover, Z-Gly-Ala-Tyr-Bert has potential applications as a precursor for radiolabeling studies, where the tyrosine residue can be iodinated or tritiated for receptor binding and biodistribution experiments. As a defined tripeptide with orthogonal protection, Z-Gly-Ala-Tyr-Bert offers peptide chemists a reliable intermediate for the construction of larger peptide chains via convergent synthesis strategies, enabling the assembly of complex peptides with improved yield and purity compared to linear stepwise approaches.

Product Parameters

Why Cosperpharm?

When your fragment condensation strategy or protease specificity study requires a reliably protected tripeptide building block, Cosperpharm delivers Z-Gly-Ala-Tyr-Bert with the analytical documentation and supply chain reliability that peptide synthesis customers demand.

Peptide assembly begins with the right protecting group strategy. The orthogonal Z/tert‑butyl ester protecting scheme of Z-Gly-Ala-Tyr-Bert enables selective deprotection — Z removed by hydrogenation, tert‑butyl ester by TFA — allowing for flexible synthetic design. Any impurity or incorrect stereochemistry in this fragment will propagate through subsequent coupling steps and compromise final peptide purity. Cosperpharm’s analytical release protocol includes HPLC purity verification, identity confirmation by mass spectrometry, and chiral purity assessment — because your synthetic success depends on the quality of this building block.

Documentation that supports your publications and regulatory filings. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. For customers developing peptide‑based therapeutics or diagnostic reagents, Cosperpharm provides DMF‑ready documentation packages, method validation reports, stability data, and custom quality agreements upon request.

Flexible supply across all development stages. Cosperpharm supplies Z-Gly-Ala-Tyr-Bert from 1g–50g quantities for method development and fragment screening, to 100g–500g batches for process validation, to kilogram‑scale for commercial manufacturing. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.

Technical support for the full synthetic cascade. Our peptide chemistry team can advise on coupling conditions compatible with the Z and tert‑butyl ester protecting groups, analytical methods for monitoring fragment condensation reactions, and deprotection strategies for final peptide assembly — because we have worked extensively with protected peptides across multiple custom synthesis campaigns.

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and academic research institutions worldwide, with full customs documentation included. Volume discounts apply at larger scales, and we communicate lead times upfront — no hidden fees, no unexpected delays.

Product Advantages

1. Orthogonal Protecting Group Strategy

Z-Gly-Ala-Tyr-Bert features orthogonal protecting groups — Z (benzyloxycarbonyl) at the N‑terminus and tert‑butyl ester at the C‑terminus — enabling selective deprotection. The Z group is cleaved by catalytic hydrogenation, while the tert‑butyl ester is removed under mild acidic conditions (TFA). This orthogonal protection scheme is essential for fragment condensation approaches in complex peptide synthesis.

2. Tripeptide Model System for Structural Studies

As a defined three‑amino acid sequence (Gly‑Ala‑Tyr), Z-Gly-Ala-Tyr-Bert serves as a minimal model system for studying peptide folding, secondary structure formation, and backbone hydrogen bonding. The tyrosine residue provides intrinsic UV absorbance for easy detection and quantitation.

3. Potential Substrate for Protease Specificity Studies

The Gly‑Ala‑Tyr tripeptide motif in Z-Gly-Ala-Tyr-Bert is recognized by certain proteases and peptidases, making this compound a potential tool for studying enzyme specificity and screening protease inhibitors. The protecting groups allow for incorporation into larger peptides or assay systems.

4. Precursor for Radiolabeling and Conjugation

The tyrosine residue in Z-Gly-Ala-Tyr-Bert can be iodinated (¹²⁵I or ¹³¹I) or tritiated for radiolabeling experiments. The N‑terminal Z group and C‑terminal tert‑butyl ester provide orthogonal protection that can be selectively removed to reveal reactive handles for conjugation to targeting vectors, imaging agents, or carrier proteins.

5. High‑Purity Peptide Building Block

Cosperpharm supplies Z-Gly-Ala-Tyr-Bert with full characterization data including HPLC purity, mass spectrometry confirmation, and chiral purity assessment — ensuring the reliability and reproducibility required for both research and manufacturing applications.

Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for Z-Gly-Ala-Tyr-Bert that meets the rigorous expectations of pharmaceutical intermediate manufacturing and peptide chemistry research applications:

Thorough analytical characterization. Each batch undergoes multi‑technique analytical release testing: HPLC purity verification, identity confirmation by mass spectrometry, chiral purity assessment, water content determination, and residual solvent analysis. Batch‑specific characterization data is provided upon request.

Full batch traceability with retention samples. From raw material procurement through synthesis, purification, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

Stability monitoring program. Cosperpharm conducts ongoing stability studies under recommended storage conditions (2–8 °C, sealed, dry). Stability summaries are updated regularly, with full data packages available to support customer research and regulatory submissions.

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch‑specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. For customers developing peptide‑based therapeutics, Cosperpharm provides DMF‑ready documentation packages, method validation reports, stability data, and custom quality agreements upon request.

Customer‑initiated quality audits. Qualified customers are welcome to audit Cosperpharm‘s manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit.

Contact Us

Interested in incorporating Z-Gly-Ala-Tyr-Bert into your next fragment condensation synthesis or peptide structural study? Cosperpharm is your trusted partner for high‑purity protected peptides and amino acid derivatives. Contact us today to request a quote, obtain a Certificate of Analysis, or discuss custom synthesis options. Our dedicated customer support team is ready to assist with product specifications, documentation, and shipment coordination. From early‑stage research to commercial manufacturing, we’re here to support your success.